FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2329002319> ?p ?o ?g. }

• W2329002319 endingPage "A84" @default.
• W2329002319 startingPage "A83.2" @default.
• W2329002319 abstract "<h3>Aims</h3> As part of the care of breast cancer patients considered for trastuzumab, the measurement of LV ejection fraction (EF) pre-treatment is required. Current protocols recommend that EF is then repeated at 3 monthly intervals following the commencement of treatment. We evaluated the use of mitral annular plane systolic excursion (MAPSE) and peak tissue Doppler velocity (Sm) in addition to EF in patients undergoing breast carcinoma treatment with trastuzumab. <h3>Methods</h3> 2D echocardiograms (n = 316) were performed by a single operator in 102 patients undergoing trastuzumab therapy. Echocardiograms were performed at baseline (n = 102), 3 mths (n = 83), 6 mths (n = 77), 9 mths (n = 39) and 12 mths (n = 15). A biplane Simpsons derived EF was measured twice and the mean calculated. MAPSE and Sm were measured in 3 consecutive cardiac cycles and the mean of these values used. Paired t-tests were used to express significant changes. <h3>Results</h3> Each of the 3 measures of LV systolic function show a significant fall over the 12 mth period (p < 0.05 vs. baseline for all measures – see Table). Absolute values for EF fell by 6.4%, MAPSE by 0.09 cm and Sm by 0.9 cm/s (all p < 0.05). During the study period there were 14 patients (13.7%) whose EF fell by >10%. In five patients (4.9 %) the EF fell within 3 mths (Group 1).In another 9 patients (8.8%) the EF declined only after 6–12 mths (Group 2). For Group 1 the mean reductions in systolic measures were: EF -11.6%, MAPSE -13% and Sm -18%. For Group 2 the changes in systolic measures at 3 mths were less (EF -1.8%; MAPSE-0.1% and Sm -6%). <h3>Conclusions</h3> In this observational study, there was a significant reduction in LV systolic function as measured by MAPSE, Sm and EF in patients undergoing trastuzumab therapy over a period of 12 months This apparent cardiotoxicity may be due to a cumulative effect of trastuzumab therapy. The decrease was greatest for Sm compared with MAPSE and EF. The reduction in EF and MAPSE were of similar magnitude. The use of Sm and MAPSE in addition to a standard biplane Simpson’s derived EF should be considered for monitoring of systolic function in those patients undergoingtrastuzumab therapy for breast cancer." @default.
• W2329002319 created "2016-06-24" @default.
• W2329002319 creator A5000311453 @default.
• W2329002319 creator A5027814408 @default.
• W2329002319 creator A5039515590 @default.
• W2329002319 creator A5060335996 @default.
• W2329002319 creator A5083044977 @default.
• W2329002319 date "2014-05-31" @default.
• W2329002319 modified "2023-09-27" @default.
• W2329002319 title "142 The Use of Tissue Doppler Imaging and Mitral Annular Plane Systolic Excursion in Addition to Ejection Fraction in Patients Undergoing Breast Cancer Treatment with Trastuzumab: Abstract 142 Table 1" @default.
• W2329002319 doi "https://doi.org/10.1136/heartjnl-2014-306118.142" @default.
• W2329002319 hasPublicationYear "2014" @default.
• W2329002319 type Work @default.
• W2329002319 sameAs 2329002319 @default.
• W2329002319 citedByCount "0" @default.
• W2329002319 crossrefType "journal-article" @default.
• W2329002319 hasAuthorship W2329002319A5000311453 @default.
• W2329002319 hasAuthorship W2329002319A5027814408 @default.
• W2329002319 hasAuthorship W2329002319A5039515590 @default.
• W2329002319 hasAuthorship W2329002319A5060335996 @default.
• W2329002319 hasAuthorship W2329002319A5083044977 @default.
• W2329002319 hasConcept C109982973 @default.
• W2329002319 hasConcept C121608353 @default.
• W2329002319 hasConcept C126322002 @default.
• W2329002319 hasConcept C164705383 @default.
• W2329002319 hasConcept C2778198053 @default.
• W2329002319 hasConcept C2779786085 @default.
• W2329002319 hasConcept C2989005 @default.
• W2329002319 hasConcept C530470458 @default.
• W2329002319 hasConcept C57900726 @default.
• W2329002319 hasConcept C71924100 @default.
• W2329002319 hasConcept C78085059 @default.
• W2329002319 hasConcept C84393581 @default.
• W2329002319 hasConceptScore W2329002319C109982973 @default.
• W2329002319 hasConceptScore W2329002319C121608353 @default.
• W2329002319 hasConceptScore W2329002319C126322002 @default.
• W2329002319 hasConceptScore W2329002319C164705383 @default.
• W2329002319 hasConceptScore W2329002319C2778198053 @default.
• W2329002319 hasConceptScore W2329002319C2779786085 @default.
• W2329002319 hasConceptScore W2329002319C2989005 @default.
• W2329002319 hasConceptScore W2329002319C530470458 @default.
• W2329002319 hasConceptScore W2329002319C57900726 @default.
• W2329002319 hasConceptScore W2329002319C71924100 @default.
• W2329002319 hasConceptScore W2329002319C78085059 @default.
• W2329002319 hasConceptScore W2329002319C84393581 @default.
• W2329002319 hasIssue "Suppl 3" @default.
• W2329002319 hasLocation W23290023191 @default.
• W2329002319 hasOpenAccess W2329002319 @default.
• W2329002319 hasPrimaryLocation W23290023191 @default.
• W2329002319 hasRelatedWork W1981850020 @default.
• W2329002319 hasRelatedWork W1996180002 @default.
• W2329002319 hasRelatedWork W2017852113 @default.
• W2329002319 hasRelatedWork W2092587751 @default.
• W2329002319 hasRelatedWork W2139448229 @default.
• W2329002319 hasRelatedWork W2149107168 @default.
• W2329002319 hasRelatedWork W2374663006 @default.
• W2329002319 hasRelatedWork W2612098439 @default.
• W2329002319 hasRelatedWork W2996098296 @default.
• W2329002319 hasRelatedWork W4239545928 @default.
• W2329002319 hasVolume "100" @default.
• W2329002319 isParatext "false" @default.
• W2329002319 isRetracted "false" @default.
• W2329002319 magId "2329002319" @default.
• W2329002319 workType "article" @default.